Abbott’s Compounding Pharmacy Recalls Products
Abbott’s Compounding Pharmacy voluntarily recalls sterile products due to lack of sterility assurance.
On Jan. 16, 2016, Abbott’s Compounding Pharmacy announced it was voluntarily recalling all unexpired lots of human and animal sterile compounded products including injectable medications, sterile solutions, eye drops, and eye ointments. The recall is in response to a concern of a lack of sterility assurance after a series of onsite FDA inspections. The recalled products were distributed in California.
The recall is cautionary and the company has not received any reports of adverse events regarding the recalled products as of Jan. 16, 2016. However, because microbial contamination could cause serious effects, the company is advising customers to stop using the products immediately and contact their healthcare provider if they experience problems related to the use of the products.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
